Apollomics Inc.: Business Overview, Financials & Competitive Analysis
Apollomics Inc. scores 3/10 on the AskCyborg Cyborg Score (Weak). Early-stage oncology biotech with promising pipeline but significant near-term liquidity and regulatory listing risks. The company received a Nasdaq noncompliance notice in June 2026 regarding minimum market value requirements, and faces cash constraints evidenced by a $2.0 million bridge loan from its CEO in March 2026 to support clinical development.
What is Apollomics Inc.'s industry? Apollomics Inc. (apollomics.com) operates in Oncology Drugs. AskCyborg classifies Apollomics Inc. under Oncology Drugs in its company registry.
Apollomics is a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. The company's pipeline focuses on targeted the...
Cyborg Score thesis
Early-stage oncology biotech with promising pipeline but significant near-term liquidity and regulatory listing...
Read the full analyst-debate transcript →Get the Latest Apollomics Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeApollomics Inc. Overview
Pro stress-test →Apollomics is a clinical-stage biopharmaceutical company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. The company's pipeline focuses on targeted therapies for difficult-to-treat cancers, with a lead program in vebreltinib for MET-altered non-small cell lung cancer and other solid tumors.
Strategic Profile
Pro stress-test →The company's primary focus is to advance global development of vebreltinib for treatment of patients with c-MET alterations, with plans to submit an IND Application for accelerated approval in NSCLC in the first half of 2027. Beyond its lead c-Met inhibitor, the pipeline includes uproleselan for acute myeloid leukemia and three new immuno-oncology candidates (APL-501, APL-502, APL-801) with mono-specific and bi-specific antibodies.
Competitive Landscape
Pro stress-test →Apollomics competes with other early-stage oncology biotech firms in targeted therapies for lung cancer and hematologic malignancies. Key competitors include Mersana Therapeutics, AnaptysBio, and Altimmune, though most peers are similarly capitalized. The company's c-Met and immuno-oncology focus positions it in crowded but high-value oncology segments where larger pharma and well-capitalized biotechs (e.g., Eli Lilly, Novartis, Roche) also compete.
Industry Context
Apollomics Inc. operates in Oncology Drugs.
Key facts
Founded: 2015 · Headquarters: Foster City, US · Revenue: $8.5M · Market cap: $32.2M